Executive Summary
British American Tobacco has rebounded +3.18% since the last report to £4,379, recovering approximately half of the previous week's decline and stabilizing YTD gains at +3.92%. The recovery follows positive developments in BAT's regulatory battle against illicit vapes, with the U.S. International Trade Commission launching a formal investigation that could reduce the illegal e-cigarette market by one-third. Despite this operational progress, mounting reputational and legal pressures from Formula 1 nicotine pouch sponsorships and UK shareholder lawsuits over North Korea sanctions breaches continue to weigh on long-term risk perception.
Key Updates
BAT has recovered +3.18% to £4,379 since the March 9 report, partially reversing the -2.50% decline reported previously. YTD performance has improved to +3.92% from +0.71%, though remains below the +5.93% level recorded on March 6. The recovery coincides with two significant developments: the U.S. International Trade Commission's formal probe into illicit vaping products and escalating public pressure regarding Formula 1 sponsorship activities. The price action suggests market participants view the ITC investigation as materially positive for BAT's U.S. vaping business, offsetting reputational concerns from tobacco sponsorship controversies.
Current Trend
BAT maintains a modest upward trajectory with +3.92% YTD gains, though momentum has weakened considerably from the +8.33% peak achieved on March 3. The stock has exhibited volatility over the past week, declining -5.44% from March 3-9 before recovering +3.18% in the current period. The 6-month performance of +5.26% demonstrates resilience amid structural industry challenges. Short-term resistance appears at the £4,464 level (March 3 high), while support has established around £4,244 (March 9 low). The current price of £4,379 positions the stock in the middle of this trading range, suggesting consolidation following recent volatility.
Investment Thesis
BAT's investment case centers on its dual-track strategy: extracting maximum cash flow from declining combustible tobacco while building leadership in reduced-risk products (vapes, heated tobacco, nicotine pouches). The company's new categories revenue reached £3.62 billion in 2025 (+7% at constant currencies), representing 14% of total revenue. Velo nicotine pouches are gaining U.S. market share against Philip Morris's Zyn and Altria's On!, supported by higher nicotine strengths and promotional strategies. However, the thesis faces headwinds from illicit vape competition (estimated at 70% of U.S. e-cigarette sales), declining traditional cigarette volumes, and operational challenges including the closure of BAT's South African factory due to 75% illicit market penetration. The regulatory environment presents both risk and opportunity: successful ITC action could restore market share, while sponsorship controversies and sanctions-related litigation create reputational and financial liabilities.
Thesis Status
The investment thesis remains intact but faces near-term execution risks. The ITC investigation represents a critical inflection point that could validate BAT's U.S. vaping strategy by reducing illicit competition from an estimated 70% to approximately 47% of market share. This would materially improve the economics of BAT's Vuse brand and accelerate new categories growth. However, the thesis confronts three significant challenges: (1) reputational damage from Formula 1 sponsorships potentially restricting future marketing channels for reduced-risk products, (2) shareholder litigation over North Korea sanctions creating financial and governance uncertainty, and (3) operational setbacks in key markets like South Africa where illicit trade has forced factory closure. The company's strong financial performance—pretax profit of £9.86 billion (+179% YoY) and adjusted operating profit of £11.89 billion exceeding consensus—provides financial flexibility to navigate these challenges. The 2% dividend increase to 245.04 pence demonstrates management confidence in cash generation despite transformation costs.
Key Drivers
The most significant near-term catalyst is the U.S. International Trade Commission investigation into illicit vaping products following BAT subsidiary Reynolds American's complaint against 16 companies. BAT estimates this action could reduce the illegal e-cigarette market by approximately one-third, though any impact is unlikely before 2027 due to supply chain timelines and existing inventories. The CEO's February statement indicated a full ITC determination is expected in March with a subsequent 60-day presidential review period. Separately, reputational pressures are intensifying as over 160 health organizations have called on Formula 1 to terminate BAT's McLaren sponsorship promoting Velo nicotine pouches, arguing the partnership exposes approximately 4 million children aged 8-12 in the EU and U.S. to nicotine marketing. Additionally, shareholder litigation over alleged failures to properly disclose North Korea sanctions breaches (resulting in $635 million in U.S. penalties in 2023) creates ongoing legal and governance risks.
Technical Analysis
BAT is trading at £4,379, positioned between near-term resistance at £4,464 (March 3 high) and support at £4,244 (March 9 low). The recent +3.18% recovery from oversold conditions suggests short-term buying interest, though the stock remains -1.90% below the March 3 peak. The 5-day decline of -3.27% and 1-month decline of -1.73% indicate persistent selling pressure, while the 6-month gain of +5.26% demonstrates medium-term resilience. YTD performance of +3.92% lags the broader market recovery but reflects stabilization after early March weakness. Volume patterns suggest institutional repositioning following the ITC announcement, with the current consolidation likely to resolve based on regulatory developments over the next 60-90 days. A break above £4,464 would target the psychological £4,500 level, while failure to hold £4,244 support could retest the £4,200 area.
Bull Case
- ITC Investigation Could Restore U.S. Vaping Market Share: The formal ITC probe targeting illicit vaping products could reduce the illegal market from 70% to approximately 47% of U.S. e-cigarette sales, materially benefiting BAT's Vuse brand and accelerating new categories revenue growth beyond the current 7% rate.
- Strong Financial Performance Exceeding Expectations: BAT delivered pretax profit of £9.86 billion (+179% YoY) and adjusted operating profit of £11.89 billion, exceeding consensus estimates of £11.29 billion, demonstrating robust cash generation capability to fund transformation initiatives.
- Velo Gaining U.S. Market Share in High-Growth Nicotine Pouches: Velo nicotine pouches are capturing market share from Philip Morris's Zyn and Altria's On! through higher nicotine strengths and promotional strategies, positioning BAT competitively in the fastest-growing reduced-risk category.
- New Categories Revenue Growth at £3.62 Billion: The company's new categories revenue rose 7% at constant currencies to £3.62 billion, representing 14% of total revenue and demonstrating successful portfolio transformation despite competitive pressures.
- Dividend Growth Signals Management Confidence: The board declared a 2% dividend increase to 245.04 pence per share, reflecting confidence in sustainable cash generation and commitment to shareholder returns amid transformation investments.
Bear Case
- Shareholder Litigation Over North Korea Sanctions Breaches: BAT faces lawsuits from over 100 shareholders regarding alleged failures to disclose sanctions violations that resulted in $635 million in U.S. penalties, creating material financial and reputational risks with undisclosed potential liabilities.
- Reputational Damage From Formula 1 Sponsorship Controversy: Over 160 health organizations are pressuring F1 to ban tobacco sponsorships, with BAT's McLaren partnership exposing the company to regulatory restrictions and potentially limiting future marketing channels for reduced-risk products across multiple jurisdictions.
- Illicit Vape Competition Remains Dominant Despite ITC Action: Even with successful ITC intervention, BAT estimates illegal vapes would still represent approximately 47% of the U.S. market, with no material impact expected before 2027 due to supply chain timelines and existing inventories, prolonging revenue headwinds.
- South African Factory Closure Signals Market Share Deterioration: BAT is closing its sole South African factory after illicit cigarettes reached 75% market share, demonstrating the company's vulnerability to illegal trade in key emerging markets and setting a concerning precedent for other geographies.
- Structural Decline in Traditional Cigarette Volumes: Overall group revenue declined 1% to £25.61 billion with combustible products facing persistent volume declines, while competitor Philip Morris has achieved 41.5% smoke-free revenue share compared to BAT's 14%, indicating BAT is lagging in the transformation race.